Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Kane Biotech Inc KNBIF


Primary Symbol: V.KNE

Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired from research institutions. DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revive are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.


TSXV:KNE - Post by User

Comment by KevinOlearyon Sep 11, 2024 3:24pm
35 Views
Post# 36219092

RE:RE:RE:RE:RE:Technical analysis

RE:RE:RE:RE:RE:Technical analysisThere is no way to be conservative and somewhat accurate when you're dealing with the FDA because you have zero idea how long they will dither. For example, the Revyve product approval has no labelling claims other than it is a hydrogel. They didn't claim it works well, or even that the hydrogel deals with biofilms etc. It is my understanding that there is nothing on the label except this is a hydrogel. How long did that take to get approval, 6 months? It should have been approved in a week.

The dispersin trials will be much more complicated because kne will put the label claims that they are trying to prove in the application, and they need guidance from the FDA about what has to be proven to the FDA, in order to get the FDA to allow those claims. If you wanted a conservative estimate of when the FDA would stop delaying this process of asking questions from hell which any biofilm scientist already knows the answers to, so trial would begin, then KNE would have said "within 10 years." 
<< Previous
Bullboard Posts
Next >>